Chemify’s AI-powered platform to transform drug and materials discovery

Drug discovery and materials development stalls for years due to manual synthesis limits, with chemists unable to explore vast chemical spaces or reliably scale complex molecules for therapies and advanced applications. These delays hinder progress in areas like infectious diseases and novel materials, where speed and precision could transform outcomes.​

Glasgow-based Chemify, launched in 2022 from the University of Glasgow by CEO Lee Cronin, reprograms chemistry via "Chemputation", blending AI, robotics, and proprietary programming language to convert digital designs into real molecules. The system crafts ideal compounds, runs synthesis and refines libraries for pharma and materials partners to access hard-to-build structures and cut timelines.

The company has received $1.6 million from the Bill & Melinda Gates Foundation to advance tuberculosis drug discovery alongside Lgenia.

Sources: Chemify | Crunchbase

Founders: Lee Cronin